Science Sub-journal: The replication RNA COVID-19 vaccine triggers a powerful immune response in non-human primates.

!--:pagetitle"--25 (UPI) -- --- In a new study, researchers from research institutions such as the University of Washington found that a replication RNA vaccine made with lipid nanoparticle emulsions could produce antibodies against THE COVID-19 coronavirus,, or SARS-CoV-2, after an immunity in mice and non-human primates.
these antibodies can effectively neutralise the virus.
these effects occur within two weeks of the vaccine being given through a muscle injection. The level of antibody produced by
was comparable to that of the coVID-19 recoverer.
the vaccine was able to strongly induce the neutralizing of the coronavirus in young and older mice.
promising findings were well received by the researchers because of concerns that older people are less likely to respond to vaccinations because of aging immune systems.
related findings published online July 20, 2020 in the journal Science Translational Medicine, with the title "An alphavirus-derived replion RNA vaccine-food-coV-2 neutralizing antibody and T cell s in mice and nonhuman primates."
the paper's author Deborah Heydenberg Fuller of the University of Washington. The first author of the
paper is Jesse H. Erasmus, a postdoctoral researcher at Fuller Labs.
the design and preparation of the replica RNA COVID-19 vaccine, in pictures from Science Translational Medicine, 2020, doi:10.1126/scitranslmeded.abc9396.
the susceptibility of older people to severe COVID-19 increases with age, and vaccination stakes for this high-risk group are an important goal for scientists.
As laboratory studies have shown, the vaccine is designed to avoid an immune response that may enhance respiratory diseases caused by the coronavirus.
, instead, it directs the immune response to more protective antiviral measures.
in addition to producing antibodies that block infection, the vaccine can induce T-cells, which can provide a second line of defense if the antibodies cannot completely block the infection.
as COVID-19 continues to spread, the discovery and widespread distribution of safe and effective vaccines is essential to defeat ingenuity of the epidemic.
there are dozens of vaccine candidates around the world that are in different stages of testing, from preclinical studies to human clinical trials. "Ideally, a vaccine that blocks COVID-19 can induce protective immunity after only one immunisation, avoid an immune response that may exacerbate the pathological process of virus-induced, be easy to scale up and produce rapidly and cost-effectively, and induce immunity in all populations, including older adults who are generally less responsive to the vaccine,"
Fuller wrote.
," she added.
", "She thinks traditional nucleic acid vaccines are promising, but at least two immunizations are needed to provide immunity."
most DNA vaccines require high doses to reach the protective levels required by humans.
traditional messenger RNA (mRNA) vaccines are formulated with lipid nanoparticles to improve their effectiveness, but may face obstacles in mass production and shelf life.
to try to overcome these limitations, Fuller Labs and her co-authors developed a version of the coronavirus vaccine for a replication RNA.
replication RNA can express more protein and trigger a stress response that senses the virus, stimulating other immune activations. the development of a
of replicated RNA vaccines for other infectious diseases and cancers is also in the pipeline at several research institutions.
in the case of this COVID-19 vaccine, RNA enters cells and instructs them to produce proteins that teach the body to recognize coronaviruses and attack them with antibodies and T cells.
such an attack could prevent the virus from fusing into cells or injecting their genetic code to control cell activity.
these antibodies, which are induced by the vaccine, protect against the coronal protein that interferes with the coronavirus.
the replication RNA vaccine contains new lipid inorganic nanoparticles developed by Seattle biotech company HDT Bio Corp. (THE COMPANY, THE COMPANY). "We are excited to work with the University of Washington to move our RNA vaccine platform forward," said Steve Reed, co-author of the
paper and CEO of HDT. "RNA molecules are highly susceptible to enzyme degradation," added Amit P. Khandhar, co-author of the
paper and lead author of the paper.
LION is a new generation of nanoparticle agents that protect RNA molecules and deliver the vaccine in vivo after a simple mixing step in a pharmacy.
"This nanoparticle enhances the vaccine's ability to trigger the required immune response, but also its stability."
the vaccine remained stable at room temperature for at least a week.
If it is proven safe and effective in human clinical trials, its ingredients will allow it to be manufactured in large quantities quickly.
the researchers predict that fewer doses of vaccines will be produced to immunize populations.
a key difference between LION and other lipid nanoparticle delivery vectors used in other mRNA COVID-19 vaccines is its ability to be formulated at the bedside by simple mixing with mRNA.
two vials supported by LION allow the manufacture of this new lipid inorganic nanoparticle independent of the mRNA component.
the researchers are working to advance the vaccine to Phase I human clinical trials, in which it is made available to a small group of healthy volunteers to gather preliminary data on whether it is safe and produces the required immune response.
(bioon.com) References: 1.Jesse H. Erasmus et al. An alphavirus-derived replicon RNA vaccine smh-CoV-2 sing antibody and T cell sydd yn mice and nonhuman primates. Science Translational Medicine, 2020, doi: 10.1126/scitranslmed.abc9396.2.COVID-19 replicating RNA has robust rinn non-human-human-human trials title"-!--/ewebeditor:page."